This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Body, J.-J. Articles by Bekker, P. J. Search for Related Content PubMed PubMed Citation Articles by Body, J.-J. Articles by Bekker, P. J.

A Study of the Biological Receptor Activator of Nuclear Factor-B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer

Authors' Affiliations: ¹ Department of Medicine, Institut Jules Bordet, Brussels, Belgium; ² Service Des Maladies du Sang, CHU de Lille, Lille, France; ³ Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom; ⁴ Division of Hematology/Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania; and ⁵ Amgen, Inc., Thousand Oaks, California

Requests for reprints: Jean-Jacques Body, Department of Medicine, Institut Jules Bordet, Rue Héger Bordet 1, B-1000 Brussels, Belgium. Phone: 32-2-541-3303; Fax: 32-2-541-3310; E-mail: jj.body{at}bordet.be.

Purpose: Receptor activator of nuclear factor-B ligand (RANKL) is essential for the differentiation, function, and survival of osteoclasts, which play a key role in establishment and propagation of skeletal disease in patients with multiple myeloma or bone metastases as well as many other skeletal diseases. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, was developed to treat patients with skeletal diseases.

Experimental Design: This was a randomized, double-blind, double-dummy, active-controlled, multicenter study to determine the safety and efficacy of denosumab in patients with breast cancer (n = 29) or multiple myeloma (n = 25) with radiologically confirmed bone lesions. Patients received a single dose of either denosumab (0.1, 0.3, 1.0, or 3.0 mg/kg s.c.) or pamidronate (90 mg i.v.). Bone antiresorptive effect was assessed by changes in urinary and serum N-telopeptide levels. Pharmacokinetics of denosumab also were assessed.

Results: Following a single s.c. dose of denosumab, levels of urinary and serum N-telopeptide decreased within 1 day, and this decrease lasted through 84 days at the higher denosumab doses. Pamidronate also decreased bone turnover, but the effect diminished progressively through follow-up. Denosumab injections were well tolerated. Mean half-lives of denosumab were 33.3 and 46.3 days for the two highest dosages.

Conclusions: A single s.c. dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days. The decrease in bone turnover markers was similar in magnitude but more sustained than with i.v. pamidronate.

This article has been cited by other articles:

				A. Marathe, M. C. Peterson, and D. E. Mager Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 555 - 562. [Abstract] [Full Text] [PDF]

				L. Gehrig, J. Lane, and M. I. O'Connor Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374. [Full Text] [PDF]

				N. Raje, S.-B. Woo, K. Hande, J. T. Yap, P. G. Richardson, S. Vallet, N. Treister, T. Hideshima, N. Sheehy, S. Chhetri, et al. Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw Clin. Cancer Res., April 15, 2008; 14(8): 2387 - 2395. [Abstract] [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				D. Vega, N. M. Maalouf, and K. Sakhaee The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4514 - 4521. [Abstract] [Full Text] [PDF]

				C. R. Chu, M. S. McMahon, Y. Ueki, and D. P. Fyhrie On the Horizon From the ORS J. Am. Acad. Ortho. Surg., October 1, 2007; 15(10): 636 - 638. [Full Text] [PDF]

				A. Lipton, G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.-J. Body, R. de Boer, R. Berardi, P. Gascon, K. S. Tonkin, et al. Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases J. Clin. Oncol., October 1, 2007; 25(28): 4431 - 4437. [Abstract] [Full Text] [PDF]

				J.-J. Body Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin. Cancer Res., October 15, 2006; 12(20): 6258s - 6263s. [Abstract] [Full Text] [PDF]

				A. Lipton Future treatment of bone metastases. Clin. Cancer Res., October 15, 2006; 12(20): 6305s - 6308s. [Abstract] [Full Text] [PDF]

				M. R. Smith Bisphosphonates for Metastatic Bone Disease -- Too Much of a Good Thing? IBMS BoneKEy, September 1, 2006; 3(9): 24 - 27. [Full Text] [PDF]